Latest News

Tolerability With Brentuximab Vedotin Treatment in Hodgkin Lymphoma
Tolerability With Brentuximab Vedotin Treatment in Hodgkin Lymphoma

May 24th 2023

During a Targeted Oncology™ Case-Based Roundtable™ event, Craig Moskowitz, MD, discussed the use of brentuximab vedotin in patients with Hodgkin lymphoma. This is the second of 2 articles based on this event.

FDA Awards FTD of IMPT-314 for B-Cell Mediated Malignancies
FDA Awards FTD of IMPT-314 for B-Cell Mediated Malignancies

May 16th 2023

FDA Grants SGX301 a Type A Meeting for the Treatment of CTCL
FDA Grants SGX301 a Type A Meeting for the Treatment of CTCL

May 15th 2023

FDA Approves Polatuzumab Vedotin Plus R-CHP for Treatment-Naïve DLBCL
FDA Approves Polatuzumab Vedotin Plus R-CHP for Treatment-Naïve DLBCL

April 19th 2023

FDA Requests Additional Study of SGX301 for Early-Stage CTCL in Type A Meeting
FDA Requests Additional Study of SGX301 for Early-Stage CTCL in Type A Meeting

April 14th 2023

Video Series
Video Interviews
Podcasts

More News